ModernaMRNA
MRNA
About: Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Employees: 5,800
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
28% more repeat investments, than reductions
Existing positions increased: 255 | Existing positions reduced: 199
0.37% more ownership
Funds ownership: 71.87% [Q4 2024] → 72.24% (+0.37%) [Q1 2025]
7% less funds holding
Funds holding: 729 [Q4 2024] → 676 (-53) [Q1 2025]
13% less funds holding in top 10
Funds holding in top 10: 8 [Q4 2024] → 7 (-1) [Q1 2025]
22% less call options, than puts
Call options by funds: $800M | Put options by funds: $1.03B
31% less first-time investments, than exits
New positions opened: 88 | Existing positions closed: 127
31% less capital invested
Capital invested by funds: $11.5B [Q4 2024] → $7.9B (-$3.6B) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$25
23%
downside
Avg. target
$37
13%
upside
High target
$70
114%
upside
6 analyst ratings
1 positive
17%
3 neutral
50%
2 negative
33%
B of A Securities Dimple Gosai | 23%downside $25 | Underperform Maintained | 22 Jul 2025 |
JP Morgan Jessica Fye | 20%downside $26 | Underweight Maintained | 22 May 2025 |
UBS Eliana Merle | 114%upside $70 | Buy Maintained | 2 May 2025 |
Barclays Gena Wang | 22%upside $40 | Equal-Weight Maintained | 2 May 2025 |
RBC Capital Luca Issi | 14%downside $28 | Sector Perform Maintained | 2 May 2025 |
Financial journalist opinion
Based on 41 articles about MRNA published over the past 30 days
Neutral
Zacks Investment Research
15 hours ago
Curious about Moderna (MRNA) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Moderna (MRNA) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Negative
Zacks Investment Research
15 hours ago
Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?
MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.
Positive
Zacks Investment Research
1 day ago
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
Neutral
Accesswire
1 day ago
Moderna Announces Data to be Presented at ESMO Congress 2025
CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, which will be held October 17-21, 2025 in Berlin, Germany. This includes a mini oral presentation on mRNA-4359, Moderna's investigational mRNA-based therapy designed to elicit T-cell immune responses against tumor and immunosuppressive cells, as well as two poster presentations on intismeran autogene (V940/mRNA-4157).
Positive
The Motley Fool
3 days ago
Down 74% Over the Past Year, Is Moderna Stock a Buy?
In the short term, Moderna (MRNA 0.41%) looks like a bad bet. It's coming off of the momentum of its COVID-19 vaccine, and doesn't have a lot of new ammo ready yet to expand in new directions.
Positive
Reuters
4 days ago
EU regulator backs Moderna's updated COVID vaccine
The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the vaccine maker said on Friday.
Positive
Zacks Investment Research
4 days ago
Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Accesswire
4 days ago
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision CAMBRIDGE, MA / ACCESS Newswire / July 25, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for an updated formulation of the COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. Following the CHMP's positive opinion, the European Commission will make a marketing authorization decision on Moderna's updated COVID-19 vaccine for the 2025-2026 season.
Negative
Zacks Investment Research
5 days ago
Moderna (MRNA) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Moderna (MRNA) closed at $34.01, marking a -1.9% move from the previous day.
Neutral
Benzinga
6 days ago
What's Going On With Moderna Stock Wednesday?
Moderna Inc.'s MRNA stock has surged approximately 37% in the last month but has dipped around 15% year to date.
Charts implemented using Lightweight Charts™